kras mutation and glutathion The roles of in cancer metabolism, tumor microenvironment clinical therapy | Molecular Cancer KRAS-Mutant Lung Cancer: Targeting Molecular
KRAS Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions PMC KRAS OriGene Technologies Inc. Targeting KRAS Mutant Cancers with a Covalent G12C Specific Inhibitor: Cell Targeting KRAS mutant stomach colorectal tumors by disrupting the ERK2 p53 complex ScienceDirect Uncovering new therapeutic targets for a common KRAS mutation behind cancer
Pay in 4 interest-free payments of $6.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




